Bone Health Technologies (BHT) announced that pre-orders are now open for Osteoboost, the first and only FDA-cleared non-drug prescription treatment for postmenopausal women with osteopenia.

Osteoboost is a wearable medical device, worn low around the waist, that delivers targeted vibration therapy directly to the hips and spine—targeting the areas most at risk of osteoporotic fractures. It includes a patented combination of dynamically calibrated frequency and amplitude, which has proven to reduce the loss of spine bone density by 85% and bone strength by 83% in a pivotal clinical trial.

“Osteoboost was developed as part of an overarching vision to provide people with a safe, convenient, and non-invasive solution to protect bone density and prevent fractures,” said Laura Yecies, CEO of Bone Health Technologies. “This is an exciting milestone for our team and the thousands of people who have patiently waited as we completed our clinical trial, successfully navigated the FDA De Novo clearance process, and begun manufacturing. We are deeply grateful for those who have taken this journey with us, and those joining us as we begin to ship devices to patients soon.”

“Vibration therapy has shown promising results in clinical trials, offering a safe and effective way to encourage bone growth,” said Dr. Yevgeniya Kushchayeva, MD, an endocrinologist at USF Health Morsani Center for Advanced Healthcare and an expert in bone density therapies. “The concept of using low-intensity vibration to mimic the effects of exercise on bone remodeling has deep-rooted foundations in bone science. I like the approach Osteoboost has taken to deliver vibration therapy directly to the hips and spine, and the clinical trial results speak for themselves. I’m looking forward to seeing Osteoboost perform in the real world and tracking results with my patients.”

Osteoboost is now available for self-pay pre-order, expected to ship in the next 60-90 days. A special Founder’s Program offer to existing waitlist members has already sold out, and the company is accelerating production to meet the high demand.